LDLR and atherosclerosis: PCSK9i reduce the risk of developing ASCVD through LDLR-dependent and LDLR-independent mechanisms, including inflammation, plaque formation, and thrombosis (Luquero et al., 2021; Hummelgaard et al., 2023).